Sign up to save your podcasts
Or
Share Revumenib
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Revumenib
The 1st menin inhibitor, revumenib, is approved for relapsed/refractory acute leukemias.
Understanding the Pathway: https://doi.org/10.1200/JCO-24-01265
View all episodes
By John Bossaer
4.9
179179 ratings
The 1st menin inhibitor, revumenib, is approved for relapsed/refractory acute leukemias.
Understanding the Pathway: https://doi.org/10.1200/JCO-24-01265
More shows like OncoPharm
View all
JAMA Editors' Summary
126 Listeners
NEJM This Week
319 Listeners
JAMA Clinical Reviews
479 Listeners
The Curbsiders Internal Medicine Podcast
3,318 Listeners
Up First from NPR
56,083 Listeners
Core IM | Internal Medicine Podcast
1,086 Listeners
The ONS Podcast
196 Listeners
ASCO Guidelines
44 Listeners
Real Life Pharmacology - Pharmacology Education for Health Care Professionals
695 Listeners
OncLive® On Air
21 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
318 Listeners
The Curious Clinicians
365 Listeners
WolverHeme Happy Hour
28 Listeners
Two Onc Docs
165 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
37 Listeners